Regorafenib‑induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report | Zendy

Shiro Kimbara | Zendy; Yoshinori Imamura | Zendy; Kimikazu Yakushijin | Zendy; Ako Higashime | Zendy; Taiji Koyama | Zendy; Yoshimi Fujishima | Zendy; Yohei Funakoshi | Zendy; Masanori Toyoda | Zendy; Naomi Kiyota | Zendy; Hiroshi Matsuoka | Zendy; Hironobu Minami | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Regorafenib‑induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report

Author(s) -

Shiro Kimbara,

Yoshinori Imamura,

Kimikazu Yakushijin,

Ako Higashime,

Taiji Koyama,

Yoshimi Fujishima,

Yohei Funakoshi,

Masanori Toyoda,

Naomi Kiyota,

Hiroshi Matsuoka,

Hironobu Minami

Publication year - 2020

Publication title -

molecular and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.442

H-Index - 7

eISSN - 2049-9469

pISSN - 2049-9450

DOI - 10.3892/mco.2020.2192

Subject(s) - regorafenib , thrombocytopenic purpura , medicine , exacerbation , immune system , adverse effect , colorectal cancer , concomitant , cancer , immunology

Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research